Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation

J Hislop; Z Quayyum; A Elders; C Fraser; D Jenkinson; G Mowatt; P Sharma; L Vale; R Petty

doi:10.3310/hta15250

Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation

J Hislop, Z Quayyum, A Elders, C Fraser, D Jenkinson, G Mowatt, P Sharma, L Vale, R Petty

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

5 Downloads (Pure)

Abstract

Imatinib dose escalation is advocated for gastrointestinal stromal tumour (GIST) treatment, but its effectiveness compared with sunitinib and best supportive care (BSC) after failure at the 400 mg/day dose is unknown.

Original language	English
Pages (from-to)	1-178
Number of pages	178
Journal	Health Technology Assessment
Volume	15
Issue number	25
DOIs	https://doi.org/10.3310/hta15250
Publication status	Published - 2011

Access to Document

10.3310/hta15250

Hislop 2011Final published version, 1.54 MB

Fingerprint

Dive into the research topics of 'Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation'. Together they form a unique fingerprint.

Cite this

Hislop, J., Quayyum, Z., Elders, A., Fraser, C., Jenkinson, D., Mowatt, G., Sharma, P., Vale, L., & Petty, R. (2011). Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation. Health Technology Assessment, 15(25), 1-178. https://doi.org/10.3310/hta15250

Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day : a systematic review and economic evaluation. / Hislop, J; Quayyum, Z; Elders, A; Fraser, C; Jenkinson, D; Mowatt, G; Sharma, P; Vale, L; Petty, R.

In: Health Technology Assessment, Vol. 15, No. 25, 2011, p. 1-178.

Research output: Contribution to journal › Article › peer-review

Hislop, J, Quayyum, Z, Elders, A, Fraser, C, Jenkinson, D, Mowatt, G, Sharma, P, Vale, L & Petty, R 2011, 'Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation', Health Technology Assessment, vol. 15, no. 25, pp. 1-178. https://doi.org/10.3310/hta15250

Hislop J, Quayyum Z, Elders A, Fraser C, Jenkinson D, Mowatt G et al. Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation. Health Technology Assessment. 2011;15(25):1-178. https://doi.org/10.3310/hta15250

Hislop, J ; Quayyum, Z ; Elders, A ; Fraser, C ; Jenkinson, D ; Mowatt, G ; Sharma, P ; Vale, L ; Petty, R. / Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day : a systematic review and economic evaluation. In: Health Technology Assessment. 2011 ; Vol. 15, No. 25. pp. 1-178.

@article{8a015860943a41859600b38868afb5bd,

title = "Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation",

abstract = "Imatinib dose escalation is advocated for gastrointestinal stromal tumour (GIST) treatment, but its effectiveness compared with sunitinib and best supportive care (BSC) after failure at the 400 mg/day dose is unknown.",

author = "J Hislop and Z Quayyum and A Elders and C Fraser and D Jenkinson and G Mowatt and P Sharma and L Vale and R Petty",

year = "2011",

doi = "10.3310/hta15250",

language = "English",

volume = "15",

pages = "1--178",

journal = "Health Technology Assessment",

issn = "1366-5278",

publisher = "National Co-ordinating Centre for HTA",

number = "25",

}

TY - JOUR

T1 - Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day

T2 - a systematic review and economic evaluation

AU - Hislop, J

AU - Quayyum, Z

AU - Elders, A

AU - Fraser, C

AU - Jenkinson, D

AU - Mowatt, G

AU - Sharma, P

AU - Vale, L

AU - Petty, R

PY - 2011

Y1 - 2011

N2 - Imatinib dose escalation is advocated for gastrointestinal stromal tumour (GIST) treatment, but its effectiveness compared with sunitinib and best supportive care (BSC) after failure at the 400 mg/day dose is unknown.

AB - Imatinib dose escalation is advocated for gastrointestinal stromal tumour (GIST) treatment, but its effectiveness compared with sunitinib and best supportive care (BSC) after failure at the 400 mg/day dose is unknown.

U2 - 10.3310/hta15250

DO - 10.3310/hta15250

M3 - Article

C2 - 21689502

VL - 15

SP - 1

EP - 178

JO - Health Technology Assessment

JF - Health Technology Assessment

SN - 1366-5278

IS - 25

ER -